Skip to main content

Thank you for visiting You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

Biomanufacturing, from bust to bubble?

Has a worldwide shortage in biomanufacturing capacity turned to a glut in just 4 years? A building boom and advances in technology threaten to derail adoption of potentially cheaper transgenic manufacturing platforms.

This is a preview of subscription content, access via your institution

Relevant articles

Open Access articles citing this article.

Access options

Rent or buy this article

Prices vary by article type



Prices may be subject to local taxes which are calculated during checkout

Figure 1: Will market demand outpace capacity? Projections show a potential shortfall by 2008 for mammalian cell culture (top) and for microbial cell culture (bottom).
Figure 2: Duckweed production line.


  1. Molowa, D. Industry Analysis: The State of Biologics Manufacturing (J.P. Morgan Securities, New York, March 12, 2001).

    Google Scholar 

  2. Biotechnology Industry Organization. Advantages of plants to produce therapeutic proteins (BIO, Washington, DC, 2004).

  3. Fox, S. Maximizing outsourced biopharma production. Contract Pharma, 72–78 (June 2004).

Download references

Author information

Authors and Affiliations


Rights and permissions

Reprints and Permissions

About this article

Cite this article

Thiel, K. Biomanufacturing, from bust to bubble?. Nat Biotechnol 22, 1365–1372 (2004).

Download citation

  • Issue Date:

  • DOI:

This article is cited by


Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing